Clinical Trials · NCT07859150
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
- Phase
- Phase 4
- Recruitment status
- Not Yet Recruiting
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Enrollment
- 104
- Start date
- Oct 2026
- Locations
- 1 site, Egypt
- Primary endpoint
- Mean percentage change in body weight from randomization